3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase NA
1
Phase 3
1
Phase 2/3
1
Phase 1/2
1
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell
1
Lung Neoplasms
1
Hot Flashes
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Breast Neoplasms
1
Interventions
Carboplatin
67
Cisplatin
57
Paclitaxel
42
Radiotherapy
35
Pemetrexed
34
Gemcitabine
31
Docetaxel
31
Etoposide
25
pembrolizumab
21
Vinorelbine
20
Erlotinib Hydrochloride
13
Magnetic Resonance Spectroscopy
12
Gefitinib
11
Specimen Handling
10
Radiosurgery
10
Drug Therapy
10
Bevacizumab
10
durvalumab
9
Nivolumab
9
Vinblastine
6
Topotecan
6
Surgical Procedures, Operative
6
Cyclophosphamide
6
atezolizumab
5
Standard of Care
5
Platinum
5
Immunoglobulin G
5
Ifosfamide
5
Disulfides
5
Dexamethasone
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Lung Neoplasms
×
Folic Acid
×
Clear all
NCT04786964
2025-04-02
CONTERNO
Checkpoint Therapeutics, Inc.
Phase 3
Terminated
25 enrolled
10 charts